ResQ133A

recombinant Mycobacterium (rMBCG) · ImmunityBio, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ResQ133A, covering 2026-03-27 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG [Phase 1, Phase 2]

See pricing